Benzinga | Jun 22, 2021 10:51AM EDT

Caladrius Bioscience To Start Testing Its CD34+ Cell Therapy in Diabetic Kidney Disease

* The FDA has signed off Caladrius Bioscience Inc's (NASDAQ:CLBS) investigational new drug application for the study of CLBS201 for the treatment of diabetic kidney disease ("DKD").

* The company plans to initiate a Phase 1/2 proof-of-concept study of CLBS201 within the next several months.

* Price Action: CLBS shares are up 0.06% at $1.56 during the market session on the last check Tuesday.